Organism: Homo sapiens
Gene: 38787_at
Selected probe(set): 211012_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38787_at (211012_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):3.6234407
Number of Samples:7 / 8

Experimental	dendritic cell study 6 (gardiquimod)
	Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control	dendritic cell study 6 (untreated)
	Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

Relative Expression (log2-ratio):3.4830027
Number of Samples:4 / 8

Experimental	dendritic cell study 6 (gardiquimod; RN486)
	Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control	dendritic cell study 6 (untreated)
	Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

Relative Expression (log2-ratio):3.2473116
Number of Samples:2 / 3

Experimental	glioma study 17 (anaplastic astrocytoma; A2B5+)
	Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old.
Control	non-tumor oligodendrocyte progenitor cell sample (cortex)
	Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

Relative Expression (log2-ratio):2.99189
Number of Samples:12 / 16

Experimental	E. coli study 1
	Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours with 2.5 × 105 heat-killed E. coli.
Control	unstimulated, normal monocyte-derived macrophage sample
	Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours unstimulated.

Relative Expression (log2-ratio):2.921813
Number of Samples:2 / 3

Experimental	glioma study 17 (small cell glioblastoma; A2B5+)
	Oligodendrocyte progenitor cells (OPC) isolated from high grade small cell glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 56 ± 3 years old males.
Control	non-tumor oligodendrocyte progenitor cell sample (cortex)
	Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

Relative Expression (log2-ratio):2.725421
Number of Samples:5 / 7

Experimental	E. coli study 2
	Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours with 2.5 × 105 heat-killed E. coli.
Control	unstimulated, normal monocyte-derived macrophage sample
	Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours unstimulated.

Relative Expression (log2-ratio):2.7149649
Number of Samples:3 / 3

Experimental	glioma study 17 (glioblastoma; A2B5+)
	Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males.
Control	non-tumor oligodendrocyte progenitor cell sample (cortex)
	Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

Relative Expression (log2-ratio):2.691122
Number of Samples:4 / 4

Experimental	dendritic cell study 6 (gardiquimod; RN486)
	Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control	dendritic cell study 6 (CpG A; RN486)
	Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

Relative Expression (log2-ratio):2.6501856
Number of Samples:2 / 4

Experimental	glioma study 17 (glioblastoma; unsorted)
	Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation.
Control	non-tumor cortical tissue
	Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

Relative Expression (log2-ratio):2.5180645
Number of Samples:5 / 6

Experimental	atopic dermatitis study 21 (lesional; whole skin)
	Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control	normal skin tissue
	Full thickness skin samples isolated from healthy subjects by laser capture microdissection.